Table 2.
Antitumor efficacy analysis of patients with mGC received mDCF versus mDCX regimen.
| Response to therapy | mDCF n = 69, n (%) |
mDCX n = 43, n(%) |
P value |
|---|---|---|---|
| Complete response | 7 (10.1) | 1 (2.3) | .15 |
| Partial response | 20 (29.0) | 16 (37.2) | .41 |
| Stable disease | 20 (29.0) | 15 (34.9) | .54 |
| Progressive disease | 22 (32.0) | 11 (25.6) | .53 |
| Objective response rate (ORR) | 27 (39) | 17 (40) | .97 |
| Disease control rate (DCR) | 47 (68) | 32 (74) | .53 |
mDCF = modified docetaxel, cisplatin, 5-FU, mDCX = modified docetaxel, cisplatin, and capecitabine, mGC = metastatic gastric cancer.